Dacomitinib For EGFR Inhibitor Resistant NSCLC`s

Dacomitinib is one of the latest advances in treatment of EGFR mutant NSCLC’s that have become resistant to reversible EGFR tyrosine kinase inhibitors. Dacomitinib differs from other EGFR inhibitors in that it irreversibly inhibits EGFR, HER2 and HER4, and shows superior activity compared to reversible EGFR inhibitors. In a recent Phase II study of patients with EGFR exon 19 or 21 mutant lung cancers, 74% of patients experienced a partial response (PR) and the preliminary median progression free survival (PFS) was an amazing 17 months.

The following is a link to a NSCLC clinical trial using Dacomitinib that is currently recruiting patients.
A Study Of Dacomitinib Vs. Erlotinib In The Treatment Of Advanced Non-Small Cell Lung Cancer.


Speak Your Mind

*